Lakewood-Amedex
Sarasota, US · Delaware corporation
Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
Founders & leadership
PA
Paul Anthony DiTullioExecutive
RF
Richard Ford HammExecutive
SP
Steve ParkinsonExecutive
Board
GE
Geoffrey E CoxBoard director
SM
Stephen M MileyBoard director
TW
Teddy Wallace BrownBoard director
Reported raises · per SEC filings
Form D private placements$31.1M disclosed across 3 rounds · 2014–2021
▶$24.1MraisedJan 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$24.1MraisedJan 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Geoffrey CoxDirector
- Charles WrightDirector
- Leonard DeRomaDirector
- Peter CorrDirector
- Offering amount
- $40M
- Amount sold
- $24.1M
- Minimum investment
- $250K
- Proceeds to insiders
- $850K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$456KraisedDec 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$456KraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Patrick Coleman O'ConnorExecutive Officer
- Peter CeccacciExecutive Officer
- Geoffrey Frank CoxDirector
- Leonard James DeRomaDirector
- Charles Frederick WrightDirector
- Offering amount
- $15M
- Amount sold
- $456K
- Minimum investment
- $100K
- Sales commissions
- $12K
- Placement agents
- Sargasso Consulting LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedSep 2015 · 75 investors · BiotechnologyRule 506(b)
▶$6.6MraisedSep 2015 · 75 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul Anthony DiTullioExecutive Officer, Director
- Geoffrey E CoxDirector
- Richard Ford HammExecutive Officer
- Steve ParkinsonExecutive Officer, Director
- Stephen M MileyDirector
- Teddy Wallace BrownDirector
- Offering amount
- $10M
- Amount sold
- $6.6M
- Minimum investment
- $26K
- Sales commissions
- $292.6K
- Proceeds to insiders
- $960K
- Placement agents
- Scarsdale Equities LLC, Capital Guardian, LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapIronwood Pharmaceuticals6 shared keywordsIronwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases. It concentrates on GI drug discovery and care for patients suffering from digestive diseases.
IQVIA6 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies competing with Lakewood-Amedex for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lakewood-Amedex do?
- Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
- How much funding has Lakewood-Amedex raised?
- Lakewood-Amedex has disclosed $31.1M raised across 3 rounds.
- Where is Lakewood-Amedex headquartered?
- Lakewood-Amedex is headquartered in Sarasota, US.